
    
      This is a single arm, open label, dose escalation clinical study to evaluate the safety and
      preliminary therapeutic efficacy of CCT303-406 cells in adult subjects with HER2 positive
      relapsed or refractory stage IV metastatic solid tumors.

      Subjects that meet inclusion criteria with positive biopsy HER2 (IHC 3+ in â‰¥50% tumor cells)
      will receive CCT303-406 according to the 3+3 dose escalation design.
    
  